カレントテラピー　36-9　サンプル page 16/28

このページは カレントテラピー　36-9　サンプル の電子ブックに掲載されている16ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　36-9　サンプル

Current Therapy 2018 Vol.36 No.9 59遺伝子プロファイル（単一のバイオマーカーでない例，未承認）891高リスク群（n＝16）中間リスク群（n＝16）低リスク群（n＝11）70CR（n＝1）PR（n＝16）NC（n＝22）PD（n＝4）Recurrencescore6050403020100図7　日本人での術前内分泌療法の効果とOncotype DXR RS〔参考文献18）より引用〕国で保険承認されており，日本乳癌学会としても，本検査の保険償還に向け，鋭意努力中である．参考文献1）Bonadonna G, Brusamolino E, Valagussa P, et al：Combinationchemotherapy as an adjuvant treatment in operablebreast cancer. N Engl J Med 294：405-410, 19762）Early Breast Cancer Trialists’Collaborative Group：Tamoxifenfor early breast cancer：an overview of the randomizedtrials. Lancet 351：1451-1467, 19983）Goldhirsch A, Wood WC, Gelber RD, et al：Meeting highlights：updated international expert consensus on the primarytherapy of early breast cancer. J Clin Oncol 21：3357-3365, 20034）Sorlie T, Perou CM, Tibshirani R, et al：Gene expression patternsof breast carcinomas distinguish tumor subclasses withclinical implications. Proc Natl Acad Sci U S A 98：10869-10874, 20015）Nielsen TO, Hsu FD, Jensen K, et al：Immunohistochemicaland clinical characterization of the basal -like subtype ofinvasive breast carcinoma. Clin Cancer Res 10：5367-5374,20046）Nguyen PL, Taghian AG, Katz MS, et al：Breast cancer subtypeapproximated by estrogen receptor, progesteronereceptor, and HER -2 is associated with local and distantrecurrence after breast-conserving therapy. J Clin Oncol26：2373-2378, 20087）Cole BF, Gelber RD, Gelber S, et al：Polychemotherapy forearly breast cancer：an overview of the randomized clinicaltrials with quality-adjusted survival analysis. Lancet 358：277-286, 20018）Naoi Y, Kishi K, Tanei T, et al：Development of 95-geneclassifier as a powerful predictor of recurrences in node-negativeand ER-positive breast cancer patients. Breast CancerRes Treat 128：633- 641, 2011 doi：10.1007/s10549- 010-1145-z. Epub 2010 Aug 299）Cardoso F, Van’t Veer LJ, Bogaerts J, et al：70-Gene Signatureas an Aid to Treatment Decisions in Early-Stage BreastCancer. N Engl J Med 375：717-729, 201610）Paik S, Shak S, Tang G, et al：A Multigene Assay to PredictRecurrence of Tamoxifen-Treated, Node-Negative BreastCancer. N Engl J Med 351：2817-2826, 200411）Paik S, Tang G, Shak S, et al：Gene Expression and Benefitof Chemotherapy in Women With Node-Negative, EstrogenReceptor?Positive Breast Cancer. J Clin Oncol 24：3726-3734, 200612）Paik S, Shak S, Tang G, et al：Expression of the 21 genes inthe Recurrence Score assay and prediction of clinical benefitfrom tamoxifen in NSABP study B-14 and chemotherapy inNSABP study B-20. SABCS（Abstract 105）, 200413）Sparano JA, Gray RJ, Makower DF, et al：Prospective Validationof a 21-Gene Expression Assay in Breast Cancer. NEngl J Med 373：2005-2014, 201514）Sparano JA, Gray RJ, Makower DF, et al：Adjuvant ChemotherapyGuided by a 21-Gene Expression Assay in BreastCancer：New England Journal of Medicine, 2018 , DOI：10.1056/NEJMoa180471015）Albain KS, Barlow WE, Shak S, et al；Breast Cancer Intergroupof North America：Prognostic and predictive value ofthe 21-gene recurrence score assay in postmenopausalwomen with node -positive, oestrogen -receptor -positivebreast cancer on chemotherapy：a retrospective analysis ofa randomised trial. Lancet Oncol 11：55-65, 201016）Dowsett M, Cuzick J, Wale C, et al：Prediction of risk of distantrecurrence using the 21-gene recurrence score innode-negative and node-positive postmenopausal patientswith breast cancer treated with anastrozole or tamoxifen：aTransATAC study. J Clin Oncol 28：1829-1834, 201017）Amin MB, Edge S, Greene F, et al：eds. AJCC Cancer StagingManual. 8th ed. Springer Publishing, New York, NY；201718）Akashi -Tanaka S, Shimizu C, Ando M, et al：21-Geneexpression profile assay on core needle biopsies predictsresponses to neoadjuvant endocrine therapy in breast cancerpatients. Breast 18：171-174, 2009 Epub 2009 May19）Toi M, Iwata H, Yamanaka T, et al；Japan Breast CancerResearch Group-Translational Research Group：Clinical significanceof the 21-gene signature（Oncotype DX）in Hormonereceptor-positive early stage primary breast cancer inthe Japanese population. Cancer 116：3112-3118, 201020）Yamamoto Y, Iwata H, Masuda N, et al：TransNEOS：Validationof the oncotype DX recurrence score（RS）testingcore needle biopsy samples from NEOS as predictor of clinicalresponse to neoadjuvant endocrine therapy for postmenopausalestrogen receptor positive（ER＋）, HER2 negative（HER2-）breast cancer patients［abstract］. In：Proceedingsof the 2017 San Antonio Breast Cancer Symposium；2017Dec 5-9；San Antonio, TX. Philadelphia（PA）：AACR. CancerRes 78（4 Suppl）：Abstract nr PD5-03, 2018